Storia in 6 fonti

AstraZeneca notches key FDA nod in hypertension, with an approval sweetener for Fasenra too

After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone synthase inhibitor (ASI) baxdrostat has continued to pay off. | After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone synthase inhibitor (ASI) baxdrostat has continued to pay off, with an FDA approval Monday that also advances the British pharma’s goal to strike $80 billion in revenue by the end of the decade.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

fiercepharma.comStai leggendo1 mesi fa

AstraZeneca notches key FDA nod in hypertension, with an approval sweetener for Fasenra too

originale

endpoints.news1 mesi fa

AstraZeneca's blood pressure pill approved, but competition could be around the corner

One of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been approved by the FDA, the drugmaker said Monday.

Leggi questa versione → originale

biopharmadive.com1 mesi fa

FDA approves AstraZeneca’s new kind of hypertension drug

Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that should ultimately generate $5 billion or more in annual sales.

Leggi questa versione → originale

medpagetoday.com1 mesi fa

FDA Greenlights Novel Hypertension Pill for Tough-to-Treat Patients

Aldosterone synthase inhibitor baxdrostat indicated as add-on to other antihypertensives

Leggi questa versione → originale

statnews.com1 mesi fa

AstraZeneca picks up FDA approval for hypertension drug

The China question, FDA leadership shakeups, and other biotech news from The Readout

Leggi questa versione → originale

healio.com1 mesi fa

Baxfendy approved for uncontrolled hypertension

AstraZeneca announced the FDA approved baxdrostat for uncontrolled hypertension as add-on therapy on top of standard care.Baxdrostat (Baxfendy) is the first aldosterone synthase inhibitor approved to treat uncontrolled…

Leggi questa versione → originale

Timeline cronologica

lunedì 18 maggio 2026·biopharmadive.com
FDA approves AstraZeneca’s new kind of hypertension drug
Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that should ultimately generate $5 billion or more in…
lunedì 18 maggio 2026·healio.com
Baxfendy approved for uncontrolled hypertension
AstraZeneca announced the FDA approved baxdrostat for uncontrolled hypertension as add-on therapy on top of standard care.Baxdrostat (Baxfendy) is the first aldosterone synthase…
lunedì 18 maggio 2026·endpoints.news
AstraZeneca's blood pressure pill approved, but competition could be around the corner
One of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been approved by the FDA, the drugmaker said Monday.
lunedì 18 maggio 2026·medpagetoday.com
FDA Greenlights Novel Hypertension Pill for Tough-to-Treat Patients
Aldosterone synthase inhibitor baxdrostat indicated as add-on to other antihypertensives
lunedì 18 maggio 2026·fiercepharma.com
AstraZeneca notches key FDA nod in hypertension, with an approval sweetener for Fasenra too
After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone synthase inhibitor (ASI) baxdrostat has continued to pay off. | After an…
lunedì 18 maggio 2026·statnews.com
AstraZeneca picks up FDA approval for hypertension drug
The China question, FDA leadership shakeups, and other biotech news from The Readout